U.S. markets closed

Unum Therapeutics to Host Third Quarter 2018 Financial Results Conference Call and Webcast on November 12, 2018 at 4:30 P.M. ET

CAMBRIDGE, Mass., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (UMRX), a clinical-stage biopharmaceutical company focused on the development of cellular immunotherapies based on its novel, universal Antibody-Coupled T-cell Receptor (ACTR) technology platform, today announced that the company will host a conference call and live audio webcast on Monday, November 12, 2018 at 4:30 p.m. ET to discuss financial results for the third quarter of 2018.  Unum management will also provide an update on the Company’s recent progress and upcoming milestones.

Participants may access the conference call by dialing 866-300-3411 (domestic) or 636-812-6658 (international) and refer to conference ID number 2287146. To join the live webcast, please visit the investor relations section of the Unum Therapeutics website at https://investors.unumrx.com/ at least 10 minutes before the event begins.

A webcast replay will be available at the same location on the Unum Therapeutics website beginning approximately two hours after the event, and will be archived for 90 days.

About Unum Therapeutics

Unum Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immunotherapy products designed to harness the power of a patient’s immune system to cure cancer. Unum’s novel proprietary technology, antibody-coupled T cell receptor (ACTR) is a universal, engineered cell therapy intended to be used in combination with a wide range of tumor-specific antibodies to target different tumor types. ACTR087 and ACTR707, each used in combination with rituximab, an anti-CD20 antibody, are Unum’s two most advanced product candidates, currently in Phase I clinical testing in adult patients with relapsed or refractory non-Hodgkin lymphoma (r/r NHL). The Company has an additional product candidate in Phase I clinical testing: ACTR087 used in combination with the novel antibody SEA-BCMA in adult patients with relapsed or refractory multiple myeloma. Finally, the Company has an active investigational new drug application (IND) for ACTR707 used in combination with trastuzumab, an anti-human epidermal growth factor receptor 2 (HER2) antibody, to treat patients with HER2+ advanced cancer. This Phase I trial is expected to be initiated by the end of 2018.

The Company is headquartered in Cambridge, MA.

Investor Contact:

Stern Investor Relations, Inc.
Stephanie Ascher, 212-362-1200 

Media Contact:

Paul Kidwell, 617-680-1088